Latest news
Tirzepatide Demonstrates Cardioprotective Effects in T2D With ASCVD - HCPLiveHCPLive · Sun, 09 Aug 2026 19:03:02 GMTNew cholesterol guideline expands treatment eligibility to 55% of U.S. adults - Managed Healthcare ExecutiveManaged Healthcare Executive · Fri, 07 Aug 2026 16:43:55 GMTZEUS Tells Us Inflammation Might Not Be the Answer - Cardiac WireCardiac Wire · Thu, 06 Aug 2026 10:22:53 GMTCardiovascular Risk Management in T2D with established ASCVD: Current Evidence for Dapagliflozin and... - Medical DialoguesMedical Dialogues · Wed, 05 Aug 2026 05:13:30 GMTZEUS Trial: Ziltivekimab Fails to Reduce MACE in ASCVD Patients - TCTMD.comTCTMD.com · Mon, 03 Aug 2026 17:05:08 GMTLink between liver fibrosis in MASLD, ASCVD varies by glycemic status - Medical XpressMedical Xpress · Sat, 01 Aug 2026 01:00:01 GMTNovo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation - GlobeNewswireGlobeNewswire · Fri, 31 Jul 2026 07:00:00 GMT